Targeted drug found effective in patients who have lung cancer with certain mutations – Medical Xpress

A targeted therapy called capmatinib can provide significant benefits to patients who have advanced lung cancer with specific gene mutations, according to recently published results from a phase two clinical trial. The trial, which is published in the New England Journal of Medicine, was conducted by an international team led by investigators at Massachusetts General Hospital (MGH).
A protein called MET affects a wide range of processes within cells, and alterations that activate the MET gene, …

Click here to view the original article.